Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Novel CFI mutation in a patient with leukocytoclastic vasculitis may redefine the clinical spectrum of Complement Factor I deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The lectin pathway of complement: advantage or disadvantage in HIV pathogenesis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PPARs and the development of Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. L-serine: a neglected amino acid with a potential therapeutic role in diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  5. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Roberto Di Marco
  • Katia Mangano
  • Cinzia Quattrocchi
  • Rosario Musumeci
  • Anna Maria Speciale
  • Gianpaolo Papaccio
  • Karsten Buschard
  • Klaus Bendtzen
  • Ferdinando Nicoletti
View graph of relations
Fusidic acid and sodium fusidate (fusidin) are antibiotics with low toxicity and powerful immunomodulatory activities in vitro and in vivo. In this study we have evaluated the effect of fusidin on the development of dinitrobenzenesulfonic acid (DNB)-induced colitis in rats that serves as a preclinical model of human inflammatory bowel disease (IBD). The data show that when administered orally at the dose of 80 (but not 40) mg/kg body wt under a "therapeutic" regimen soon after DNB application, fusidin significantly ameliorates clinical, histological, and seroimmunological signs of disease. These entailed a significant reduction in body weight loss, smaller increase in colon weights, milder macroscopic damage, and lower histological scores. In addition, when sacrificed at the end of the study, fusidin-treated rats had significantly lower blood levels of tumor necrosis factor alpha and interferon-gamma compared with untreated controls. The present findings concur with the beneficial actions of fusidin in a pilot study conducted in patients with Crohn's disease and warrant controlled studies in humans with IBD.
Original languageEnglish
JournalClinical Immunology
Volume109
Issue number3
Pages (from-to)266-71
Number of pages6
ISSN1521-6616
Publication statusPublished - 1 Dec 2003

ID: 32259111